Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Amortizatization of Intangibles (2021 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Amortizatization of Intangibles for 9 consecutive years, with $38000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Amortizatization of Intangibles fell 73.79% to $38000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $87000.0, a 52.63% increase, with the full-year FY2024 number at $874000.0, up 186.56% from a year prior.
  • Amortizatization of Intangibles was $38000.0 for Q3 2025 at NovaBay Pharmaceuticals, up from -$7000.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $979000.0 in Q3 2023 to a low of -$814000.0 in Q4 2023.
  • A 5-year average of $76066.7 and a median of $60000.0 in 2021 define the central range for Amortizatization of Intangibles.
  • Peak YoY movement for Amortizatization of Intangibles: plummeted 553.33% in 2022, then soared 987.78% in 2023.
  • NovaBay Pharmaceuticals' Amortizatization of Intangibles stood at $60000.0 in 2021, then tumbled by 553.33% to -$272000.0 in 2022, then crashed by 199.26% to -$814000.0 in 2023, then surged by 100.37% to $3000.0 in 2024, then skyrocketed by 1166.67% to $38000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Amortizatization of Intangibles are $38000.0 (Q3 2025), -$7000.0 (Q2 2025), and $53000.0 (Q1 2025).